External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Dr. Reddy's Laboratories / Equity Bottom-Up

<ul><li>The company reported a 19.9% YoY revenue growth, aided by the acquired NRT business, which contributed Rs 597 Cr. Excluding NRT, the underlying revenue growth stood at 11.5% YoY.</li><li>North American operations witnessed muted growth due to pricing pressure and lower sales of select products, though partially offset by new product launches and volume gains.</li><li>The India business grew 15.8% YoY, while the Europe business, excluding NRT, posted a robust 30% YoY increase. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The company reported a 19.9% YoY revenue growth, aided by the acquired NRT business, which contributed Rs 597 Cr. Excluding NRT, the underlying revenue growth stood at 11.5% YoY.North American operations witnessed muted growth due to pricing pressure and lower sales of select products, though partially offset by new product launches and volume gains.The India business grew 15.8% YoY, while the Europe business, excluding NRT, posted a robust 30% YoY increase. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr. Reddy’s Laboratories Ltd - Short-Term Margin Headwinds; Long-Term Pipeline Strength